Loading…
Avaria Health & Beauty Corp., a Canadian drug manufacturer, failed to comply with Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, rendering their over-the-counter drug products adulterated. During an April 2024 inspection, the FDA identified that the firm failed to conduct required identity testing on incoming drug components, including high-risk ingredients, and did not perform USP identification tests to verify component safety limits. The violations indicated inadequate quality assurance procedures for components used in manufacturing, with the firm unable to verify the identity of each component shipment and lot used in their OTC products.